Important Note: Submissions due by Wednesday 4 October
Crohn’s & Colitis Australia urges its members to have their say about the potential listing of Entocort (budesonide) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Crohn’s disease.
The manufacturers of Entocort have recently made an application to Pharmaceutical Benefits Advisory Committee (PBAC) for their product to be made available to patients through the PBS. The application relates to patients who have mild ileal or ileocolonic Crohn’s disease, and would benefit greatly if provided affordable access to an oral, locally acting Corticosteroids such as budesonide that have less severe side effects than most commonly used steriods.
PBS is the main mechanism via which the Government subsidises the cost of medications used by the community.
As part of its evaluation of products the PBAC asks for public comments from patients, carers, members of the public, health professionals or consumer interest groups. These comments help the PBAC assess if the community needs access to therapies.
Patients, carers, members of the public, health professionals and consumer interest groups are able to have their say on whether this additional therapy for people with moderate to severe UC should be made available through subsidy on the PBS.
Crohn’s & Colitis Australia has made a submission in support of this application.
Have your say by accessing the ‘Consumer Input Form’. Once the form is completed and the SUBMIT button pressed, the form will be sent electronically to the PBAC Secretariat and an email confirmation of receipt is received which will include a copy of your comments. This form is also available in hardcopy on request from the PBAC Secretariat on (02) 6289 7099.
The PBAC meeting is scheduled for the 1 – 3 of November 2017 and you may submit the form from now until Wednesday 4 October 2017.
CCA would also like to hear your comments and personal stories so that we can better advocate for your needs. Please email all comments to email@example.com